Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit ReviewGW 441756 is a potent, selective inhibitor of the NGF receptor tyrosine kinase A (TrkA) (IC50 = 2 nM). Displays > 100-fold selectivity over a range of other kinases.
Sold for research purposes under agreement from GlaxoSmithKline.
M. Wt | 275.31 |
Formula | C17H13N3O |
Storage | Store at RT |
Purity | ≥99% (HPLC) |
CAS Number | 504433-23-2 |
PubChem ID | 16219401 |
InChI Key | NXNQLECPAXXYTR-UHFFFAOYSA-N |
Smiles | CN1C=C(C=C2C(=O)NC3=CC=CN=C23)C2=C1C=CC=C2 |
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Solvent | Max Conc. mg/mL | Max Conc. mM | |
---|---|---|---|
Solubility | |||
DMSO | 4.13 | 15 |
The following data is based on the product molecular weight 275.31. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
0.15 mM | 24.22 mL | 121.08 mL | 242.15 mL |
0.75 mM | 4.84 mL | 24.22 mL | 48.43 mL |
1.5 mM | 2.42 mL | 12.11 mL | 24.22 mL |
7.5 mM | 0.48 mL | 2.42 mL | 4.84 mL |
References are publications that support the biological activity of the product.
Wood et al (2004) Discovery and in vitro evaluation of potent TrkA kinase inhibitors: oxindole and aza-oxindoles. Bioorg.Med.Chem.Lett. 14 953 PMID: 15013000
If you know of a relevant reference for GW 441756, please let us know.
Keywords: GW 441756, GW 441756 supplier, Potent, selective, TrkA, inhibitors, inhibits, Neurotrophin, Receptors, Receptor, Tyrosine, Kinases, RTKs, GW441756, GlaxoSmithKline, GSK, Trk, 2238, Tocris Bioscience
Citations are publications that use Tocris products. Selected citations for GW 441756 include:
Lawn et al (2015) Neurotrophin signaling via TrkB and TrkC receptors promotes the growth of brain tumor-initiating cells. Nat Chem Biol 290 3814 PMID: 25538243
Rees et al (2016) Correlating chemical sensitivity and basal gene expression reveals mechanism of action. Oncotarget 12 109 PMID: 26656090
Donatien et al (2018) Granulocyte-macrophage colony-stimulating factor receptor expression in clinical pain disorder tissues and role in neuronal sensitization. Pain Rep 3 e676 PMID: 30534627
Edwards et al (2011) Effect of brain- and tumor-derived connective tissue growth factor on glioma invasion. J Natl Cancer Inst 103 1162 PMID: 21771732
Wang et al (2008) Cellular assays for high-throughput screening for modulators of Trk receptor tyrosine kinases. Curr Chem Genomics 1 27 PMID: 20161825
Do you know of a great paper that uses GW 441756 from Tocris? Please let us know.
There are currently no reviews for this product. Be the first to review GW 441756 and earn rewards!
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.
Huntington's disease (HD) is a severe monogenic neurodegenerative disorder, which is characterized by the prevalent loss of GABAergic medium spiny neurons (MSN) in the striatum. This poster summarizes the effects of mutant huntingtin aggregation implicated in the pathology of HD, as well as highlighting the use of iPSCs for HD modeling.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.